Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)



Status:Active, not recruiting
Conditions:Cardiology, Ocular, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:3/28/2019
Start Date:January 15, 2019
End Date:June 1, 2019

Use our guide to learn which trials are right for you!

Drug Utilization Study in Patients Receiving Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

A retrospective, non-interventional, observational, multi-center, drug utilization study to
be conducted in adult participants with visual impairment due to DME treated with Ozurdex
implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.


Inclusion Criteria:

- Patient received at least two Ozurdex implants in the study eye to treat visual
impairment due to DME

- First Ozurdex implant injection occurred after 1 January 2015

- Patient was followed-up at the site for at least 12 months after the first Ozurdex
implant in the study eye

Exclusion Criteria:

- Participant received Ozurdex implants as part or during a clinical study
We found this trial at
1
site
Irvine, California 92622
?
mi
from
Irvine, CA
Click here to add this to my saved trials